Dibromsalan

Summary

Dibromsalan (CHEMBL21869) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 371.02 Da · C13H9Br2NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL21869
Name	Dibromsalan
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	14839
Molecular formula	C13H9Br2NO2
Molecular weight	371.02
InChIKey	CTFFKFYWSOSIAA-UHFFFAOYSA-N

SMILES: C1=CC(=CC=C1NC(=O)C2=C(C=CC(=C2)Br)O)Br

IUPAC name: 5-bromo-N-(4-bromophenyl)-2-hydroxybenzamide

Also known as: Dibromsalan, NSC-20527, DIBROMSALAN

Patent coverage: 248 distinct patent families (659 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 656 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).